Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 35.7× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| SYRE | VTV | |
|---|---|---|
Market Cap | $7.35B | $262.40B |
Volume | 1,624,631 | 2,800,630 |
Sector | Health | — |
52-Week High | $108.92 | $227.51 |
52-Week Low | $22.18 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VTV trades at $220.67, down 0.34% on the day, with a bullish technical signal supported by moving averages but mixed oscillators. The ETF shows strong institutional interest with recent acquisitions by QRG Capital Management and Blue Edge Capital. Recent news highlights VTV's 2.3% dividend yield and value-focused strategy outperforming growth counterparts in 2026, with value stocks gaining traction amid market rotation away from tech concentration.
VTV presents a compelling value proposition with low 0.03% fees and income appeal, though long-term performance trails the S&P 500. Key risks include sustained growth stock dominance and interest rate sensitivity. The ETF's diversification across value stocks positions it well for investors seeking stability amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
